FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients...
Source: prnewswire.com
Page 14 - Project Orbis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Project Orbis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Project Orbis Today - Breaking & Trending Today
Daiichi Sankyo Company, Limited (DSKYF) Q1 2022 Results - Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2022 Earnings Conference Call July 29, 2022 2:00 AM ETCompany ParticipantsHiroyuki Okuzawa - Head, Corporate Planning and Management...
Source: seekingalpha.com
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class
Source: finanznachrichten.de
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Enhertu granted Priority Review for HER2-low mBC
Investegate announcements from AstraZeneca PLC, Enhertu granted Priority Review for HER2-low mBC
Source: investegate.co.uk
